https://scholars.lib.ntu.edu.tw/handle/123456789/458562
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | LIN-CHAU CHANG | en_US |
dc.contributor.author | CHIH-FEN HUANG | en_US |
dc.contributor.author | Lai M.-S. | en_US |
dc.contributor.author | LI-JIUAN SHEN | en_US |
dc.contributor.author | FE-LIN LIN WU | en_US |
dc.contributor.author | WEN-FANG CHENG | en_US |
dc.creator | Chang L.-C.;Huang C.-F.;Lai M.-S.;Shen L.-J.;Wu F.-L.L.;Wen-Fang Cheng | - |
dc.date.accessioned | 2020-02-14T02:49:40Z | - |
dc.date.available | 2020-02-14T02:49:40Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | 2-s2.0-85044530403 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/458562 | - |
dc.description.abstract | The overall survival (OS) of patients with ovarian cancer is poor while epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer. The aim of the present study was to evaluate the clinico-pathologic characteristics, especially the prognostic factors, for patients with epithelial ovarian cancer (EOC) in Taiwan. Information about newly diagnosed patients with EOC from 2009 to 2012 was retrieved from the database of the Taiwan Cancer Registry. Data from 2009 to 2013 for the respective cases from the claims database of Taiwan's National Health Insurance and National Death Registry were then retrieved. Potential prognostic factors were analyzed. The mean age at diagnosis of the 2,498 patients was 52.8 years. Serous carcinoma and clear cell carcinoma were diagnosed in 43.3% and 22.8% of the total patients, respectively. For patients with early-stage disease, taxane-based adjuvant chemotherapy, stage I, and younger age at diagnosis led to better overall survival (p = 0.030, p = 0.002, p<0.001, respectively) in multivariable analysis. For advanced-stage patients, histology (endometrioid type), taxane-based adjuvant chemotherapy, stage, and age at diagnosis had a significant impact on OS (p<0.001, p = 0.020, p<0.001, p<0.001, respectively). In conclusion, taxane-based chemotherapy impacts the outcome of patients with EOC. Personalized medicine may be needed for different histological types of EOC because of their different outcomes. ? 2018 Chang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | - |
dc.relation.ispartof | PLoS ONE | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | antineoplastic agent; bridged compound; taxane; taxoid; adenocarcinoma; adjuvant chemotherapy; adult; aged; cancer staging; carcinoma; female; human; middle aged; mortality; multivariate analysis; neoplasm; ovary tumor; pathology; prognosis; register; survival rate; young adult; Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents; Bridged-Ring Compounds; Carcinoma; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prognosis; Registries; Survival Rate; Taxoids; Young Adult | - |
dc.title | Prognostic factors in epithelial ovarian cancer: A population-based study | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1371/journal.pone.0194993 | - |
dc.identifier.scopus | 56601533000 | - |
dc.relation.journalvolume | 13 | - |
dc.relation.journalissue | 3 | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Pharmacy | - |
crisitem.author.dept | School of Pharmacy | - |
crisitem.author.dept | Pharmacy | - |
crisitem.author.dept | Pharmacy-NTUH | - |
crisitem.author.dept | School of Pharmacy | - |
crisitem.author.dept | Clinical Pharmacy | - |
crisitem.author.dept | Office of International Affairs | - |
crisitem.author.dept | Clinical Pharmacy | - |
crisitem.author.dept | Pharmacy | - |
crisitem.author.dept | Obstetrics & Gynecology | - |
crisitem.author.dept | Obstetrics & Gynecology-NTUH | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Surgery-NTUCC | - |
crisitem.author.orcid | 0000-0001-7441-9355 | - |
crisitem.author.orcid | 0000-0003-1311-8828 | - |
crisitem.author.orcid | 0000-0002-2854-3205 | - |
crisitem.author.orcid | 0000-0002-5813-1172 | - |
crisitem.author.orcid | 0000-0002-3282-6304 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | Administrative Unit | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。